



Appl. No: 10/522,004
Docket No: EX03-054C-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Rice, *et al.*
Application No.: 10/522,004
Filed: January 14, 2005
For: RECEPTOR-TYPE MODULATORS AND
METHODS OF USE

Confirmation No.: 5083
Attorney Docket No.: EX03-054C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant notes that Citation Nos. 1 and 2 of the Information Disclosure Statement in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application.

In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.

In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required, as the disclosure is submitted prior to the first office action on the merits. However, if this belief is in error, the Commissioner is authorized to charge any required fees to deposit account no. 50-1108.

Respectfully submitted,

Dated: March 21, 2005

Michael Atkins
Michael Atkins Reg. No. 35,431
EXELIXIS, INC.
170 Harbor Way, P.O. Box 511
South San Francisco, California 94083-0511
Telephone: (650) 837-8304
Facsimile: (650) 837-8234

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Attorney Docket Number

Complete if Known

Application Number

10/522 004

Filing Date

1-14-2005

First Named Inventor

Rice

Art Unit

Examiner Name _____

Attorney Docket Number

EX03-054C-US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Jeffrey Murray/	Date Considered	03/24/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not attached. Send original and copy of this form with the communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document to be examined. ⁶ Indicate the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.M./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<div> <div>Complete if Known</div> <table> <tr> <td>Application Number</td> <td>10/522,004</td> </tr> <tr> <td>Filing Date</td> <td>1-14-2005</td> </tr> <tr> <td>First Named Inventor</td> <td>Rice</td> </tr> <tr> <td>Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>EX03-054C-US</td> </tr> </table> </div>		Application Number	10/522,004	Filing Date	1-14-2005	First Named Inventor	Rice	Art Unit		Examiner Name		Attorney Docket Number	EX03-054C-US
Application Number	10/522,004															
Filing Date	1-14-2005															
First Named Inventor	Rice															
Art Unit																
Examiner Name																
Attorney Docket Number	EX03-054C-US															
<div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(Use as many sheets as necessary)</div> </div>																
Sheet	2	of	2													

[illegible]

Examiner Signature	/Jeffrey Murray/	Date Considered	03/24/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designator number (optional). * Applicant is to place a check mark here if English language Translation is attached.
The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Rice, *et al.*
Application No.: 10/522,004
Filed: January 14, 2005
For: RECEPTOR-TYPE MODULATORS AND
METHODS OF USE

Confirmation No.: 5083
Attorney Docket No.: EX03-054C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The Chemical Abstracts Registry (CAS[®]) database was queried to identify structures that are identical or related to the structures recited in the claims of the above-referenced patent application. The following patent publications were identified:

EP0875506, PFIZER LTD, 1998-11-04
EP0880508, ZENECA LTD, 1998-12-02
EP0912570, GLAXO GROUP LTD, 1999-05-06
EP0973746, AMERICAN CYANAMID CO, 2000-01-26
EP0977737, JANSSEN PHARMACEUTICA NV, 2000-02-09
EP1304110, GLAXO GROUP LTD, 2003-04-23
EP1340748, NIPPON SHINYAKU CO LTD., 2003-09-03
EP1044969, PFIZER PROD INC, 2000-10-18
EP1117653, ASTRAZENECA AB, 2001-07-25
EP1243582, KIRIN BREWERY, 2002-09-25
US5650415, SUGEN INC, 1997-07-22
US5770599, ZENECA LTD, 1998-06-23
US6103728, SUGEN INC, 2000-08-15
US6288082, AMERICAN CYANAMID CO, 2001-09-11
US6344459, WARNER LAMBERT CO, 2002-02-05
US6476031, SCIOS INC, 2002-11-05
US6521618, AMERICAN HOME PROD, 2002-02-28
US6521629, PFIZER INC, 2003-02-18
US6525046, BOEHRINGER INGELHEIM PHARMA, 2003-02-25
US6552027, PARKER HUGHES INST, 2002-10-31
US6562818, WARNER LAMBERT CO, 2003-05-13
US6593333, ASTRAZENECA AB, 2003-07-15
US6602836, UNILEVER HOME & PERSONAL CARE, 2003-04-17
US6608048, AMERICAN HOME PROD, 2003-04-03
US6608071, Novartis AG, 2003-08-19

US6627634, BOEHRINGER INGELHEIM PHARMA KG, 2003-09-30
US6630489, ASTRAZENCA AB, 2003-10-07
US6642242, PFIZER INC, 2003-11-04
US6649620, PFIZER INC, 2003-11-18
US6653305, BOEHRINGER INGELHEIM PHARMA KG, 2003-11-25
US6656946, BOEHRINGER INGELHEIM PHARMA KG, 2003-12-02
US6673803, ZENECA LIMITED, 2004-01-06
US6723726, SMITHKLINE BEECHAM CORPORATION, 2004-04-20
US6727256, SMITHKLINE BEECHAM CORPORATION, 2004-04-27
US6740651, BOEHRINGER INGELHEIM PHARMA KG, 2004-05-25
US2002032208, ZENECA LTD, 2002-03-14
US2002137757, PARKER HUGHES INST, 2002-09-26
US2002161010, CHAKRAVARTY et al, 2002-10-31
US2002161226, PARKER HUGHES INST, 2002-10-31
US2002165243, PARKER HUGHES INST, 2002-11-07
US2002169180, HIMMELSBACH et al, 2002-11-14
US2002177601, HIMMELSBACH et al, 2002-11-28
US2002169165, KATH et al, 2002-11-14
US2002173509, HIMMELSBACH et al, 2002-11-21
US2003018029, BARKER et al, 2003-01-23
US2003013728, PARKER HUGHES INST, 2003-01-16
US2003045525, COLLIS et al, 2003-03-06
US2003045537, LEE et al, 2003-03-06
US2003065180, AMERICAN HOME PROD, 2003-04-03
US2003069230, BECKER et al, 2003-04-10
US2003069248, CHAKRAVARTY et al., 2003-04-10
US2003100573, WANG et al, 2003-05-29
US2003100753, PFIZER, 2003-05-29
US2003149056, AMERICAN CYANAMID CO, 2003-08-07
US2003149062, BOEHRINGER INGELHEIM PHARMA, 2003-08-07
US2003171386, PFIZER, 2003-09-11
US2003176451, CARTER et al, 2003-09-18
US5747498, PFIZER, 1998-05-05
US6071921, ZENECA LTD, 2000-06-06
US6126917, HADASIT MED RES SERVICE, 2000-10-03
US6235746, CELLTECH THERAPEUTICS LTD, 2001-05-22
US6238951, COMMISSARIAT ENERGIE ATOMIQUE, 2001-05-29
US2000625820, NORTH SHORE LONG ISLAND JEWISH, 2002-08-13
US6294532, ZENECA LTD, 2001-09-25
US6337335, CELLTECH THERAPEUTICS LTD, 2002-01-08
US6344455, WARNER LAMBERT CO, 2002-02-05
US6358962, HUGHES INST, 2001-08-23
US6362336, ZENECA LTD, 2002-03-14
US6391874, SMITHKLINE BEECHAM CORP, 2002-05-21

US6403580, BOEHRINGER INGELHEIM PHARMA, 2002-06-11
US6414148, ZENECA LTD, 2002-07-02
US6469013, PARKER HUGHES INST, 2002-04-11
US6476031, SCIOS INC, 2002-11-05
US6476040, PFIZER, 2002-11-05
US6495556, PARKER HUGHES INST, 2001-11-22
US6514971, ZENECA LTD, 2003-02-04
US6759410, SMITHLINE BEECHAM CORP, 2004-07-06
WO0021955, ZENECA LTD, 2000-04-20
WO0047212, ASTRAZENECA UK LTD, 2000-08-17
WO0056338, PARKER HUGHES INST, 2000-09-28
WO0020402, ZENECA LTD, 2000-04-13
WO0018761, AMERICAN CYANAMID CO, 2000-04-06
WO0068201, ASTRAZENECA AB, 2000-11-16
WO0147890, KIRIN BREWERY, 2001-07-05
WO0168186, AMERICAN CYANAMID CO, 2001-09-20
WO0194341, ASTRAZENECA AB, 2001-12-13
WO0200649, ASTRAZENECA AB, 2002-01-03
WO0216352, ASTRAZENECA AB, 2002-02-28
WO0230924, ASTRAZENECA AB, 2002-04-18
WO0230926, ASTRAZENECA AB, 2002-04-18
WO0234744, ASTRAZENECA AB, 2002-05-02
WO0055141, BOEHRINGER INGELHEIM PHARMA, 2000-09-21
WO0121596, ASTRAZENECA AB, 2001-03-29
WO02085895, ASTRAZENECA AB, 2002-10-31
WO02092577, ASTRAZENECA AB, 2002-11-21
WO02092578, ASTRAZENECA AB, 2002-11-21
WO02092579, ASTRAZENECA AB, 2002-11-21
WO02092571, ASTRAZENECA AB, 2002-11-21
WO02088110, KIRIN BREWERY, 2002-11-07
WO0200188, COGNIS FRANCE SA, 2002-01-03
WO03000660, KIRIN BREWERY, 2003-01-03
WO03037252, MERCK & CO INC, 2003-05-08
WO03040109, ASTRAZENECA AB, 2003-05-15
WO03045395, ASTRAZENECA AB, 2003-06-05
WO03047584, ASTRAZENECA AB, 2003-06-12
WO03048159, ASTRAZENECA AB, 2003-06-12
WO03050108, PFIZER PROD INC, 2003-06-19
WO03053960, ASTRAZENECA AB, 2003-07-03
WO03055491, ASTRAZENECA AB, 2003-07-10
WO03055492, ASTRAZENECA AB, 2003-07-10
WO03055866, BAYER AG, 2003-07-10
WO03064413, ASTRAZENECA R & D SODERTALJE, 2003-08-07
WO03064421, GLAXO GROUP LTD, 2003-08-07


WO03064431, GLAXO GROUP LTD, 2003-08-07
WO03066060, BOEHRINGER INGELHEIM PHARMA, 2003-08-14
WO04035572, KIRIN BEER KABUSHIKI KAISHA, 2004-04-29
WO04054585, PFIZER PRODUCTS INC., 2004-07-01
WO04055003, NEUROGEN CORPORATION, 2004-07-01
WO04058267, ARIAD PHARMACEUTICALS, INC., 2004-07-15
WO9609294, WELLCOME FOUND, 1996-03-28
WO9615118, ZENECA LTD, 1996-05-23
WO9703069, GLAXO GROUP LTD, 1997-01-30
WO0043366, KIRIN BREWERY, 2000-07-27
WO0218351, BOEHRINGER INGELHEIM PHARMA, 2002-03-07
WO0236570, ASTRAZENECA AB, 2002-05-10
WO0244166, ASTRAZENECA AB, 2002-06-06
WO03055491, ASTRAZENECA AB, 2003-07-10
WO03089439, BOEHRINGER INGELHEIM PHARMA, 2003-10-30
WO04041829, ASTRAZENECA AB, 2004-05-21
WO9703069, GLAXO GROUP LTD, 1997-01-30
WO9722596, ZENECA LTD, 1997-06-26
WO9730035, ZENECA LTD, 1997-08-21
WO9732856, ZENECA LTD, 1997-09-12
WO9813354, ZENECA LTD, 1998-04-02
WO9910349, ZENECA LTD, 1999-03-04
WO9813350, ZENECA LTD, 1998-04-02

The above-references have not been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: March 21, 2005


Michael Atkins Reg. No. 35,431
EXELIXIS, INC.
170 Harbor Way, P.O. Box 511
South San Francisco, California 94083-0511
Telephone: (650) 837-8304
Facsimile: (650) 837-8234